Protalix BioTherapeutics (PLX) Gains from Investment Securities (2010 - 2026)
Protalix BioTherapeutics (PLX) recorded quarterly Gains from Investment Securities of $2.5 million in Q1 2026, up 181.22% quarter-over-quarter from -$3.1 million in Q4 2025, and up 7475.76% on a YoY basis from $33000.0 in Q1 2025.
Protalix BioTherapeutics (PLX) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 7475.76% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at -$565000.0 (down 276.67% YoY), while the FY2025 annual figure was $2.1 million, down 71.73% from the prior year.
- Gains from Investment Securities was $2.5 million for Q1 2026 at Protalix BioTherapeutics, up from -$3.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.5 million in Q1 2026 to a low of -$3.1 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged $53999.4 across 5 years, with a median of $99000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities tumbled 725.2% in 2025, then soared 7475.76% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at $427000.0 in 2022, then slumped by 428.81% to -$1.4 million in 2023, then soared by 73.43% to -$373000.0 in 2024, then sank by 725.2% to -$3.1 million in 2025, then soared by 181.22% to $2.5 million in 2026.
- The last three Gains from Investment Securities figures came in at $2.5 million (Q1 2026), -$3.1 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | -373,000.00 |
| Dec 31, 2024 | -373,000.00 |
| Sep 30, 2024 | 360,000.00 |
| Sep 30, 2024 | 360,000.00 |
| Jun 30, 2024 | -170,000.00 |
| Jun 30, 2024 | -170,000.00 |
| Mar 31, 2024 | 186,000.00 |
| Mar 31, 2024 | 186,000.00 |
| Dec 31, 2023 | -1.40 Mn |
| Dec 31, 2023 | -1.40 Mn |